PTTG1IP在甲状腺滤泡上皮细胞起源肿瘤中的表达及意义

目的 探讨PTTG1IP蛋白在甲状腺滤泡上皮细胞起源的不同肿瘤中的表达情况及意义。方法 应用免疫组织化学方法检测PTTG1IP蛋白在25例甲状腺癌旁正常组织、23例滤泡性腺瘤、65例乳头状癌、19例滤泡癌和18例未分化癌中的表达情况。结果 PTTG1IP蛋白表达率在甲状腺癌旁正常组织中为28%，在滤泡性腺瘤组织为30.43%，在乳头状癌组织为61.54%，在滤泡癌组织为31.58%，在未分化癌组织为22.22%。PTTG1IP蛋白在乳头状癌组织的表达率显著高于癌旁正常组织、滤泡性腺瘤组织、滤泡癌组织和未分化癌组织（P<0.05）。PTTG1IP蛋白表达率与甲状腺乳头状癌患者年龄、甲状腺外侵犯和TNM分期明显相关（P<0.05）。结论 在甲状腺滤泡上皮细胞起源的不同肿瘤中，PTTG1IP蛋白过表达可能在乳头状癌的始发和进展中发挥作用，而与滤泡癌和未分化癌的发生发展无关。PTTG1IP蛋白可能是鉴别乳头状癌与甲状腺良性病变及其他恶性滤泡上皮性肿瘤的一个有用指标。PTTG1IP可能为难治的甲状腺乳头状癌提供新的治疗靶点。

Expression and significance of PTTG1IP protein in different thyroid tumors originated from follicular epithelium

Objective To detect the expression and significance of PTTG1IP protein in different thyroid tumors originated from follicular epithelium. Methods Immunohistochemical staining was used to detect the expressions of PTTG1IP protein in 25 cases of normal thyroid, 23 cases of follicular adenoma, 65 cases of papillary thyroid carcinoma, 19 cases of follicular carcinoma and 18 cases of anaplastic carcinoma tissues. Results The positive rates of PTTG1IP protein were 28% in normal thyroid tissue, 30.43% in follicular adenoma tissue, 61.54% in papillary thyroid carcinoma tissue, 31.58% in follicular carcinoma tissue and 22.22% in anaplastic carcinoma tissue, respectively. The expression rate of PTTG1IP protein was significant higher in papillary thyroid carcinoma tissue than that in normal thyroid, follicular adenoma, follicular carcinoma and anaplastic carcinoma tissues (P<0.05). The expression rate of PTTG1IP protein was significant associated with patient age, extrathyroid invasion and TNM stage in papillary thyroid carcinoma (P<0.05). Conclusions In different thyroid tumors originated from follicular epithelia, the PTTG1IP protein over-expression may play a role in tumorgenesis and progression of papillary thyroid carcinoma particularly, whereas, it is not related with tumorgenesis of follicular carcinoma and anaplastic carcinoma. PTTG1IP protein may serve as a useful marker for discriminating papillary thyroid carcinoma from benign thyroid lesions and other malignant thyroid carcinoma. PTTG1IP may be a new therapeutic target for papillary thyroid carcinoma.